1. A computer implemented method of providing requests to a cache pipeline, the method comprising:
receiving a plurality of requests from one or more state machines at an arbiter;
selecting one of the plurality of requests as a selected request, the selected request having been provided by a state machine;
determining that the selected request requests performing an access to a particular location in the cache and a coherency check;
determining that the location in the cache is unavailable; and
converting the selected request to a request that only includes a coherency check.
2. The method of claim 1, further comprising:
notifying the first state machine that the selected request was converted.
3. The method claim 1, wherein the location in the cache is a cache line.
4. The method of claim 1, wherein the location in the cache is an interleave portion.
5. The method of claim 1, wherein the determination that the location in the cache is unavailable is made based on information in a line store coupled to the cache pipeline and configured to store information about the availability of cache lines in the cache.
6. The method of claim 5, wherein an arbiter coupled to the cache pipeline, the line store and the state machine, is configured to determine if the particular cache line is available and to convert the request.
7. The method of claim 1, wherein the cache is formed of embedded read only memory.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. Compound A having a form selected from the group consisting of:
a) Hydrate III, wherein Hydrate III is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 20.5, 5.0, and 18.2; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 5.14, 6.31, 12.49, 18.35, 26.81, 28.03, 30.33, 31.27, 34.95, 35.99, 38.68, 42.01, 54.93, 56.39, 60.14, 74.20, 107.02, 120.11, 121.60, 129.73, 134.35, 135.95, 142.89, 148.47, 155.37, 157.32, 160.90, 168.32, 172.17, and 175.53 ppm;
b) Hydrate II, wherein Hydrate II is characterized by an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 11.7, 16.6, and 11.2;
c) a crystalline Na salt characterized by an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 18.4, 9.1, and 9.8;
d) a crystalline K salt characterized by an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 18.2, 8.9, and 20.3;
e) Hydrate I, wherein Hydrate I is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 8.6, 20.6, and 26.6; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 4.22, 7.23, 11.45, 17.79, 24.04, 26.95, 28.29, 31.15, 32.47, 32.47, 33.46, 34.03, 35.74, 42.32, 53.50, 56.05, 56.96, 77.49, 108.95, 119.65, 122.55, 131.05, 133.13, 135.38, 142.28, 150.78, 156.03, 157.99, 161.36, 171.40, 173.42, 174.30 ppm;
f) Hydrate IV, wherein Hydrate IV is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 14.7, 11.5, and 7.1; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 3.90, 5.30, 6.99, 10.49, 13.13, 17.81, 24.73, 27.52, 28.14, 29.42, 31.02, 32.80, 36.08, 39.22, 42.45, 53.62, 55.93, 59.14, 60.76, 74.77, 109.22, 111.19, 11.38, 120.24, 122.50, 133.96, 139.74, 147.2, 148.90, 154.65, 158.25, 159.53, 160.12, 170.14, 171.05, 172.08, 173.47, and 174.46 ppm;
g) Hydrate V, wherein Hydrate V is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 9.1, 18.3, and 19.8; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 7.86, 8.92, 13.10, 18.31, 23.72, 27.44, 28.47, 30.77, 35.79, 36.25, 37.15, 37.15, 42.95, 53.13, 55.67, 57.31, 60.47, 62.06, 75.09, 110.59, 112.24, 118.32, 132.18, 134.05, 135.83, 139.88, 148.30, 155.19, 157.97, 159.41, 170.31 and 175.20; and
h) Hydrate VI, wherein Hydrate VI is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K\u03b1 radiation which comprises 2\u0398 values in degrees of about 20.5, 12.8, and 19.4; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 4.87, 6.24, 11.70, 12.85, 18.36, 26.55, 28.31 m 31.51, 34.98, 38.47, 42.09, 54.27, 56.12, 60.10, 73.49, 73.97, 105.91, 108.04, 118.39, 119.75, 121.33, 129.96, 133.87, 136.13, 142.26, 142.97, 146.85, 148.36, 154.97, 157.32, 160.71, 168.23, 172.21 and 175.34 ppm.
2. A pharmaceutical composition comprising a therapeutically effect amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
3. A method of treating HCV in a patient comprising the step of administering to the patient a therapeutically effective amount of a compound of claim 1.
4. The preparation of a medicament of use in treating HCV in a patient comprising an effective amount of a compound of claim 1.
5. The compound of claim 1 for use in the treatment of HCV.
6. A method of making a compound of claim 1, where said Compound A is Hydrate III, made by a process comprising crystallizing Compound A using an acetonewater ratio of 80:20 vv acetone to water to 0:100 vv acetone to water and drying.